International investors including BlackRock and Fidelity are anchoring a boom in Hong Kong biotech listings, with Chinese healthcare companies raising a record $21.1bn from share offerings in the city this year.
包括貝萊德(BlackRock)和富達(Fidelity)在內(nèi)的國際投資者正為香港掀起的一股生物科技企業(yè)上市潮充當(dāng)支柱，數(shù)據(jù)顯示，中國醫(yī)療公司今年赴港上市募得創(chuàng)紀(jì)錄的211億美元資金。
您已閱讀6%（303字），剩余94%（4558字）包含更多重要信息，訂閱以繼續(xù)探索完整內(nèi)容，并享受更多專屬服務(wù)。